These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 35337604)

  • 1. Biomarkers in muscle invasive bladder cancer.
    Wilson F; Joseph N; Choudhury A
    Adv Clin Chem; 2022; 107():265-297. PubMed ID: 35337604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic Implications of Immunohistochemical Biomarkers in Non-muscle-invasive Blad Cancer and Muscle-invasive Bladder Cancer.
    Boegemann M; Krabbe LM
    Mini Rev Med Chem; 2020; 20(12):1133-1152. PubMed ID: 27173513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating tumor DNA as a Predictive and Prognostic Biomarker in the Perioperative Treatment of Muscle-invasive Bladder Cancer: A Systematic Review.
    Crupi E; de Padua TC; Marandino L; Raggi D; Dyrskjøt L; Spiess PE; Sonpavde GP; Kamat AM; Necchi A
    Eur Urol Oncol; 2024 Feb; 7(1):44-52. PubMed ID: 37330413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Perioperative systemic therapy in muscle invasive bladder cancer: Current standard method, biomarkers and emerging strategies.
    Kim KH; Lee HW; Ha HK; Seo HK
    Investig Clin Urol; 2023 May; 64(3):202-218. PubMed ID: 37341001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant and adjuvant treatments in muscle-invasive bladder cancer: Where are we?
    Osanto S; Álvarez Gómez de Segura C
    Arch Esp Urol; 2020 Dec; 73(10):971-985. PubMed ID: 33269716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Immune and Stromal Infiltration on Outcomes Following Bladder-Sparing Trimodality Therapy for Muscle-Invasive Bladder Cancer.
    Efstathiou JA; Mouw KW; Gibb EA; Liu Y; Wu CL; Drumm MR; da Costa JB; du Plessis M; Wang NQ; Davicioni E; Feng FY; Seiler R; Black PC; Shipley WU; Miyamoto DT
    Eur Urol; 2019 Jul; 76(1):59-68. PubMed ID: 30712971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Organ preservation in muscle-invasive urothelial bladder cancer.
    Niglio SA; Purswani JM; Schiff PB; Lischalk JW; Huang WC; Murray KS; Apolo AB
    Curr Opin Oncol; 2024 May; 36(3):155-163. PubMed ID: 38573204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. History of Non-Muscle-Invasive Bladder Cancer May Have a Worse Prognostic Impact in cT2-4aN0M0 Bladder Cancer Patients Treated With Radical Cystectomy.
    Kayama E; Kikuchi E; Fukumoto K; Shirotake S; Miyazaki Y; Hakozaki K; Kaneko G; Yoshimine S; Tanaka N; Takahiro M; Kanai K; Oyama M; Nakajima Y; Hara S; Monma T; Oya M
    Clin Genitourin Cancer; 2018 Oct; 16(5):e969-e976. PubMed ID: 29778322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beyond surgery: bladder preservation and the role of systemic treatment in localised muscle-invasive bladder cancer.
    Swinton M; Devi A; Song YP; Hoskin P; Choudhury A
    World J Urol; 2024 Apr; 42(1):210. PubMed ID: 38573431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Molecular Subtyping and Immune Infiltration on Pathological Response and Outcome Following Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer.
    Necchi A; Raggi D; Gallina A; Ross JS; Farè E; Giannatempo P; Marandino L; Colecchia M; Lucianò R; Bianchi M; Colombo R; Salonia A; Gandaglia G; Fossati N; Bandini M; Pederzoli F; Capitanio U; Montorsi F; de Jong JJ; Dittamore R; Liu Y; Davicioni E; Boormans JL; Briganti A; Black PC; Gibb EA
    Eur Urol; 2020 Jun; 77(6):701-710. PubMed ID: 32165065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathological Downstaging and Survival Outcomes Associated with Neoadjuvant Chemotherapy for Variant Histology Muscle Invasive Bladder Cancer.
    Chakiryan NH; Jiang DD; Gillis KA; Green E; Hajiran A; Hugar L; Zemp L; Zhang J; Jain R; Chahoud J; Poch M; Manley BJ; Li R; Sexton W; Gilbert SM
    J Urol; 2021 Oct; 206(4):924-932. PubMed ID: 34032503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Using the neoadjuvant chemotherapy paradigm to develop precision therapy for muscle-invasive bladder cancer.
    Chedgy EC; Douglas J; Wright JL; Seiler R; van Rhijn BW; Boormans J; Todenhöfer T; Dinney CP; Collins CC; Van der Heijden MS; Black PC
    Urol Oncol; 2016 Oct; 34(10):469-76. PubMed ID: 27317490
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Significance of preoperative butyrylcholinesterase as an independent predictor of survival in patients with muscle-invasive bladder cancer treated with radical cystectomy.
    Koie T; Ohyama C; Yamamoto H; Hatakeyama S; Imai A; Yoneyama T; Hashimoto Y; Kitayam M; Hirota K
    Urol Oncol; 2014 Aug; 32(6):820-5. PubMed ID: 24951323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Perioperative therapy for muscle invasive bladder cancer.
    Leow JJ; Fay AP; Mullane SA; Bellmunt J
    Hematol Oncol Clin North Am; 2015 Apr; 29(2):301-18, ix. PubMed ID: 25836936
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myths About Bladder Preservation in Muscle-Invasive Bladder Cancer.
    Elumalai T; Joseph N; Choudhury A
    Semin Radiat Oncol; 2023 Jan; 33(1):56-61. PubMed ID: 36517194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive Biomarkers of Response to Neoadjuvant Therapy in Muscle Invasive Bladder Cancer.
    Nikkola J; Black P
    Methods Mol Biol; 2023; 2684():229-247. PubMed ID: 37410238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current Perioperative Therapy for Muscle Invasive Bladder Cancer.
    Ma J; Black PC
    Hematol Oncol Clin North Am; 2021 Jun; 35(3):495-511. PubMed ID: 33958147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A reported 20-gene expression signature to predict lymph node-positive disease at radical cystectomy for muscle-invasive bladder cancer is clinically not applicable.
    van Kessel KE; van de Werken HJ; Lurkin I; Ziel-van der Made AC; Zwarthoff EC; Boormans JL
    PLoS One; 2017; 12(3):e0174039. PubMed ID: 28319171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Meta-analysis of neoadjuvant chemotherapy compared to radical cystectomy alone in improving overall survival of muscle-invasive bladder cancer patients.
    Hamid ARAH; Ridwan FR; Parikesit D; Widia F; Mochtar CA; Umbas R
    BMC Urol; 2020 Oct; 20(1):158. PubMed ID: 33054762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment Allocation and Survival in Patients Diagnosed with Nonmetastatic Muscle-invasive Bladder Cancer: An Analysis of a National Patient Cohort in England.
    John JB; Varughese MA; Cooper N; Wong K; Hounsome L; Treece S; McGrath JS; Harden S
    Eur Urol Focus; 2021 Mar; 7(2):359-365. PubMed ID: 32088138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.